SynthesisFrontiers in medicine2026
Effects of enteral immunonutrition enriched with multiple immunonutrients on clinical outcomes of patients who underwent gastric cancer surgery: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the clinical efficacy of enteral immunonutrition (EIN) compared to standard enteral nutrition (EN) in patients undergoing gastric cancer surgery. Methods: We searched major databases for randomized controlled trials (RCTs) published up to December 2025. Nineteen RCTs involving 1,653 patients were included. Outcomes assessed included infectious and total complications, length of hospital stay (LOS), gastrointestinal tolerance, and immune-inflammatory markers. Results: Compared to EN, EIN significantly reduced the incidence of infectious complications (OR = 0.48), gastrointestinal intolerance, and total complications. It also shortened LOS (MD = -1.24 days) and time to first flatus. EIN improved immune parameters (increased IgG, IgM, IgA, transferrin) and reduced inflammatory markers (WBC, CRP). Subgroup analysis indicated that perioperative administration yielded the most significant benefits, while preoperative-only intervention lacked sufficient evidence. Intervention durations > 7 days showed superior outcomes, with regimens within 10 days offering an optimal balance of efficacy and feasibility. Conclusion: Perioperative enteral immunonutrition, particularly when administered for 7-10 days, is associated with reduced postoperative complications, improved humoral immunity, and shorter hospital stay in patients undergoing gastric cancer surgery. Given the moderate certainty of evidence for primary outcomes, the low certainty for several secondary outcomes, and the evidence of small-study effects for total complications, EIN may be considered as a component of perioperative nutritional support- particularly in patients with established nutritional risk-while routine use should be guided by individualized assessment and confirmed by larger high-quality multicenter trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.